Tvardi Q1 2025 net loss $9.6M, cash burn $7.7M; going concern doubt persists

Tvardi Therapeutics, Inc.

Net loss $9.6M ($0.50 dil EPS) vs $4.2M loss in Q1 2024; accumulated deficit $101.8M.
Revenue nil; operating expenses $4.35M (R&D $3.1M, G&A $1.2M).
Cash & equivalents $11.4M, short-term investments $10.9M at March 31; cash used in ops $7.7M.
Convertible notes $35.8M; other expense $5.5M from fair value change on notes.
Merger closed April 15, 2025 provided $23.8M cash; substantial doubt about going concern pre-merger.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.